http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2058549-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2432164db826b693ef5ff930b3e7e096 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 |
| filingDate | 1992-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1996-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b199b21c1f216df9e9641a15fc076198 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63edf9c197cf19ead36251a8489e253b |
| publicationDate | 1996-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2058549-C1 |
| titleOfInvention | Method of ischemic cardial disease sensitivity to calcium antagonists |
| abstract | FIELD: medicine. SUBSTANCE: method involves the isolation of platelets from patient blood using nystatin probe and determination of their fluorescence intensity at the 1-st and 30-th minutes. Corinfar or finoptin is prescribed at fluorescence intensity increase above 20% and less 10% or its absence, respectively. EFFECT: prognosis of treatment effectiveness of patients, individual antianginal therapy, increased secondary prophylaxis. 2 tbl |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2487353-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02057847-A1 |
| priorityDate | 1992-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.